Mendus AB (CHIX:IMMUs)

Q4 2025 Mendus AB (publ) Earnings Call Transcript

Feb 11, 2026 / 01:00 PM GMT

Release Date Price: kr32.7

Transcript

Key Points

Positve

Mendus AB (STU:1YG0) presented continued positive data from their phase 2 trial in MRD positive AML, indicating promising long-term survival rates.
The company has established a large-scale GMP production facility with NorthX Biologics, supporting future clinical development and potential commercial launch.
Mendus AB successfully raised 52.5 million Swedish crowns in a directed issue, supported by major shareholders, enhancing their financial stability.
The company secured a 50 million Swedish crown loan facility with Fena Capital, providing additional financial flexibility.
The Ellison trial in ovarian cancer confirmed the safety and feasibility of Vididenza as a potential combination therapy, showing positive long-term survival data.

Negative

Mendus AB reported a net loss of 38.7 million Swedish crowns for Q4, highlighting ongoing financial challenges.
The company underwent a reorganization, including staff reductions, to balance costs with anticipated trials in 2026.
There is uncertainty regarding the registration trial strategy in CML, as it is still in early development stages.
The recruitment rate for the Cadence trial is variable, with potential competition from new drugs affecting patient enrollment.
The company's future financing strategy remains uncertain, with reliance on potential partnerships and non-dilutive funding options.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMMUN.ST - Mendus AB (publ)
Q4 2025 Mendus AB (publ) Earnings Call
Feb 11, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Mendo's Q4 report 2025 presentation. During the Q&A session, participants are able to ask questions by dialing 5 on their telephone keypad. Now I will hand the conference over to the speakers, CEO Eric Manting and CFO Latta Firm. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you everybody for joining. Welcome to the Q4 finance and business update of Mendez on behalf of myself and our CFO lottta Fm.

Hi everyone.

Let's start with a summary of Q4. We presented continued positive data of our phase 2 trial, the Advanced 2 trial in MRD

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.